Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease

Experimental Biology and Medicine

Volumn 232, Issue 2, 2007, Pages 323-335

  Brewer, George J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 5024 Kresge Bldg II ^*  (United States)

Author keywords

Alzheimer's disease; Atherosclerosis; Copper; Iron

Indexed keywords

COPPER; IRON; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; DIABETES MELLITUS; FENTON REACTION; FIBROSIS; HUMAN; INFLAMMATION; IRON OVERLOAD; NATURAL SELECTION; PARKINSON DISEASE; REVIEW; SEX DIFFERENCE; TOXICITY;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; COPPER; HUMANS; IRON;

EID: 33846782816     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 140:98-104, 2000.
2. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 11:298-300, 1956.
3. Harman D. Prolongation of life: role of free radical reactions in aging. J Am Geriatr Soc 17:721-735, 1969.
4. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals and brain aging. Clin Geriatr Med 20:329-359, 2004.
5. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32:1050-1060, 2002.
6. Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122:945-962, 2001.
7. Butterfield DA, Boyd-Kimball D. Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 14:426-432, 2004.
8. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 1000:1-7, 2004.
9. Weinberg ED. Exposing the Hidden Dangers of Iron. Nashville: Cumberland House Publishing, Inc., 2004.
10. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873, 2004.
11. Hallberg L, Hulthen L. High serum ferritin is not identical to high iron stores [comment]. Am J Clin Nutr 78:1225-1226, 2003.
12. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med 32:833-840, 2002.
13. Polla AS, Polla LL, Polla BS. Iron as the malignant spirit in successful ageing. Ageing Res Rev 2:25-37, 2003.
14. Ramakrishna G, Rooke TW, Cooper LT. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light [see comment]. Vasc Med 8:203-210, 2003.
15. Schipper HM. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res Rev 3:265-301, 2004.
16. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1: 1293-1294, 1981.
17. Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J 145:190-194, 2003.
18. Sullivan JL. Is stored iron safe? J Lab Clin Med 144:280-284, 2004.
19. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 89:157-161, 1978.
20. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85:447-452, 1976.
21. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis [see comment]. N Engl J Med 343:522-529, 2000.
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comment]. JAMA 280:605-613, 1998.
23. You SA, Wang Q. Ferritin in atherosclerosis. Clin Chim Acta 357:1-16, 2005.
24. Lee DH, Jacobs DR. Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. Med Hypotheses 62:442-445, 2004.
25. Nakano M, Kawanishi Y, Kamohara S, Uchida Y, Shiota M, Inatomi Y, Komori T, Miyazawa K, Gondo K, Yamasawa I. Oxidative DNA damage (8- hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. Free Radic Biol Med 35:826-832, 2003.
26. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation 103:52-57, 2001.
27. Meyers DG. The iron hypothesis: does iron play a role in atherosclerosis? Transfusion 40:1023-1029, 2000.
28. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 286:901-905, 1992.
29. Thong PS, Selley M, Watt F. Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol Biol (Noisy-le-grand) 42: 103-110, 1996.
30. Vlad M, Caseanu E, Uza G, Petrescu M. Concentration of copper, zinc, chromium, iron and nickel in the abdominal aorta of patients deceased with coronary heart disease. J Trace Elem Electrolytes Health Dis 8:111-114, 1994.
31. Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 368:513-515, 1995.
32. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24:949-954, 2004.
33. Pang JH, Jiang MJ, Chen YL, Wang FW, Wang DL, Chu SH, Chau LY. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest 97:2204-2212, 1996.
34. Lee FY, Lee TS, Pan CC, Huang AL, Chau LY. Colocalization of iron and ceroid in human atherosclerotic lesions. Atherosclerosis 138:281-288, 1998.
35. Yuan XM, Anders WL, Olsson AG, Brunk UT. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 124:61-73, 1996.
36. Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 51:471-480, 2004.
37. Tuomainen TP, Diczfalusy U, Kaikkonen J, Nyyssonen K, Salonen JT. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med 35:922-928, 2003.
38. Hirano K, Ogihara T, Miki M, Yasuda H, Tamai H, Kawamura N, Mino M. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radic Res 21:267-276, 1994.
39. Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW, Balla G. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant 18(Suppl 5):v8-12, 2003.
40. Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women [see comment]. Circulation 100:1268-1273, 1999.
41. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland [see comment]. Circulation 100:1274-1279, 1999.
42. Failla M, Giannattasio C, Piperno A, Vergani A, Grappiolo A, Gentile G, Meles E, Mancia G. Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy [see comment]. Hepatology 32:569-573, 2000.
43. Niederau C. Iron overload and atherosclerosis [comment]. Hepatology 32:672-674, 2000.
44. Perry G, Sayre LM, Atwood CS, Castellani RJ, Cash AD, Rottkamp CA, Smith MA. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16: 339-352, 2002.
45. Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 24: 184-187, 2002.
46. Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, Smith MA. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 16:77-81, 2003.
47. Casadesus G, Smith A, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB, Perry G. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis 6: 165-169, 2004.
48. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 1012:179-182, 2004.
49. Ong WY, Halliwell B. Iron, atherosclerosis, and neurodegeneration: a key role for cholesterol in promoting iron-dependent oxidative damage? Ann N Y Acad Sci 1012:51-64, 2004.
50. Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 93:58-66, 2000.
51. Zambenedetti P, De Bellis G, Biunno I, Musicco M, Zatta P. Transferrin C2 variant does confer a risk for Alzheimer's disease in caucasians. J Alzheimers Dis 5:423-427, 2003.
52. Van Landeghem GF, Sikstrom C, Beckman LE, Adolfsson R, Beckman L. Transferrin C2, metal binding and Alzheimer's disease. Neuroreport 9:177-179, 1998.
53. Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum Genet 101:126-129, 1997.
54. Robson KJ, Lehmann DJ, Wimhurst VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, Warden DR, Smith AD. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 41:261-265, 2004.
55. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:1304-1308, 1991.
56. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol A Biol Sci Med Sci 59:478-493, 2004.
57. Atamna H. Heme, iron, and the mitochondrial decay of ageing. Ageing Res Rev 3:303-318, 2004.
58. Massie HR, Aiello VR, Williams TR. Inhibition of iron absorption prolongs the life span of Drosophila. Mech Ageing Dev 67:227-237, 1993.
59. Sohal RS, Farmer KJ, Allen RG, Ragland SS. Effects of diethyldithiocarbamate on life span, metabolic rate, superoxide dismutase, catalase, inorganic peroxides and glutathione in the adult male housefly, Musca domestica. Mech Ageing Dev 24:175-183, 1984.
60. Mainous AG, Gill JM, Carek PJ. Elevated serum transferrin saturation and mortality. Ann Fam Med 2:133-138, 2004.
61. Mainous AG, Wells B, Carek PJ, Gill JM, Geesey ME. The mortality risk of elevated serum transferrin saturation and consumption of dietary iron. Ann Fam Med 2:139-144, 2004.
62. Brewer GJ, Harris ED, Askari FK. Normal copper metabolism and lowering copper to subnormal levels for therapeutic purposes. In: Benhamou JP, Rizzetto M, Reichen J, Rodés J, Blei A, Eds. Textbook of Hepatology: From basic science to clinical practice. Oxford, England: Blackwell Publishing, Expected publication, 2006.
63. Hedera P, Fink JK, Bockenstedt PL, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin: further support for existence of a new zinc overload syndrome. Arch Neurol 60:1303-1306, 2003.
64. Srikumar TS, Johansson GK, Ockerman PA, Gustafsson JA, Akesson B. Trace element status in healthy subjects switching from a mixed to a lactovegetarian diet for 12 mo. Am J Clin Nutr 55:885-890, 1992.
65. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, Wang Y, Johnson V. Does a vegetarian diet control Wilson's disease? J Am Coll Nutr 12: 527-530, 1993.
66. Linder MC, Houle PA, Isaacs E, Moor JR, Scott LE. Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 24:23-35, 1979.
67. Ehrenwald E, Chisolm GM, Fox PL. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 93:1493-1501, 1994.
68. Mukhopadhyay CK, Mazumder B, Lindley PF, Fox PL. Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. Proc Natl Acad Sci U S A 94:11546-11551, 1997.
69. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 28:1735-1744, 2000.
70. Mezzetti A, Pierdomenico SD, Costantini F, Romano F, De Cesare D, Cuccurullo F, Imbastaro T, Riario-Sforza G, Di Giacomo F, Zuliani G, Fellin R. Copper/zinc ratio and systemic oxidant load: effect of aging and aging-related degenerative diseases. Free Radic Biol Med 25:676-681, 1998.
71. Mansoor MA, Bergmark C, Haswell SJ, Savage IF, Evans PH, Berge RK, Svardal AM, Kristensen O. Correlation between plasma total homocysteine and copper in patients with peripheral vascular disease. Clin Chem 46:385-391, 2000.
72. Reunanen A, Knekt P, Marniemi J, Maki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr 50:431-437, 1996.
73. Singh RB, Gupta UC, Mittal N, Niaz MA, Ghosh S, Rastogi V. Epidemiologic study of trace elements and magnesium on risk of coronary artery disease in rural and urban Indian populations. J Am Coll Nutr 16:62-67, 1997.
74. Salonen JT, Salonen R, Seppanen K, Kantola M, Suntioinen S, Korpela H. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ 302:756-760, 1991.
75. Ford ES. Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol 151:1182-1188, 2000.
76. Kok FJ, Van Duijn CM, Hofman A, Van der Voet GB, De Wolff FA, Paays CH, Valkenburg HA. Serum copper and zinc and the risk of death from cancer and cardiovascular disease. Am J Epidemiol 128: 352-359, 1988.
77. Manttari M, Manninen V, Huttunen JK, Palosuo T, Ehnholm C, Heinonen OP, Frick MH. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 15:1599-1603, 1994.
78. Klipstein-Grobusch K, Grobbee DE, Koster JF, Lindemans J, Boeing H, Hofman A, Witteman JC. Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study. Br J Nutr 81:139-144, 1999.
79. Cunningham J, Leffell M, Mearkle P, Harmatz P. Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication. Metabolism 44: 996-999, 1995.
80. Powell JT, Muller BR, Greenhalgh RM. Acute phase proteins in patients with abdominal aortic aneurysms. J Cardiovasc Surg 28:528-530, 1987.
81. Jayakumari N, Ambikakumari V, Balakrishnan KG, Iyer KS. Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis 94:183-190, 1992.
82. Belch JJ, Chopra M, Hutchison S, Lorimer R, Sturrock RD, Forbes CD, Smith WE. Free radical pathology in chronic arterial disease. Free Radic Biol Med 6:375-378, 1989.
83. Piorunska-Stolzmann M, Iskra M, Majewski W. The activity of cholesterol esterase and ceruloplasmin are inversely related in the serum of men with atherosclerosis obliterans. Med Sci Monit 7:940-945, 2001.
84. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [see comment][erratum appears in N Engl J Med 337:356, 1997]. N Engl J Med 336:973-979, 1997.
85. Manthey J, Stoeppler M, Morgenstern W, Nussel E, Opherk D, Weintraut A, Wesch H, Kubler W. Magnesium and trace metals: risk factors for coronary heart disease? Association between blood levels and angiographic findings. Circulation 64:722-729, 1981.
86. Enbergs A, Dorszewski A, Luft M, Monnig G, Kleemann A, Schulte H, Assmann G, Breithardt G, Kerber S. Failure to confirm ferritin and caeruloplasmin as risk factors for the angiographic extent of coronary arteriosclerosis. Coron Artery Dis 9:119-124, 1998.
87. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis, 2006.
88. Kim CH, Park JY, Kim JY, Choi CS, Kim YI, Chung YE, Lee MS, Hong SK, Lee KU. Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: a population-based study. Metab Clin Exp 51:838-842, 2002.
89. Dalle Lucca JJ, Saari JT, Falcone JC, Schuschke DA. Neointima formation in the rat carotid artery is exacerbated by dietary copper deficiency. Exp Biol Med (Maywood) 227:487-491, 2002.
90. Saari JT, Schuschke DA. Cardiovascular effects of dietary copper deficiency. Biofactors 10:359-375, 1999.
91. Lamb DJ, Avades TY, Allen MD, Anwar K, Kass GE, Ferns GA. Effect of dietary copper supplementation on cell composition and apoptosis in atherosclerotic lesions of cholesterol-fed rabbits. Atherosclerosis 164:229-236, 2002.
92. Lamb DJ, Reeves GL, Taylor A, Ferns GA. Dietary copper supplementation reduces atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 146:33-43, 1999.
93. Lamb DJ, Avades TY, Ferns GA. Biphasic modulation of atherosclerosis induced by graded dietary copper supplementation in the cholesterol-fed rabbit. Int J Exp Pathol 82:287-294, 2001.
94. Pham T, Kodvawala A, Hui DY. The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity. Biochemistry 44:7577-7582, 2005.
95. Nakano E, Williamson MP, Williams NH, Powers HJ. Copper-mediated LDL oxidation by homocysteine and related compounds depends largely on copper ligation. Biochim Biophys Acta 1688:33-42, 2004.
96. Apostolova MD, Bontchev PR, Ivanova BB, Russell WR, Mehandjiev DR, Beattie JH, Nachev CK. Copper-homocysteine complexes and potential physiological actions. J Inorg Biochem 95:321-333, 2003.
97. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77:1370-1376, 1986.
98. Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology 123:33-40, 1997.
99. Emsley AM, Jeremy JY, Gomes GN, Angelini GD, Plane F. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Br J Pharmacol 126:1034-1040, 1999.
100. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 272:3520-3526, 1997.
101. Ferns GA, Lamb DJ, Taylor A. The possible role of copper ions in atherogenesis: the Blue Janus [see comment]. Atherosclerosis 133: 139-152, 1997.
102. Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 271:1406-1409, 1996.
103. White AR, Multhaup G, Galatis D, McKinstry WJ, Parker MW, Pipkorn R, Beyreuther K, Masters CL, Cappai R. Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein. J Neurosci 22:365-376, 2002.
104. Angeletti B, Waldron KJ, Freeman KB, Bawagan H, Hussain I, Miller CC, Lau KF, Tennant ME, Dennison C, Robinson NJ, Dingwall C. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem 280:17930-17937, 2005.
105. Nelson TJ, Alkon DL. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 280:7377-7387, 2005.
106. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616, 1999.
107. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74:270-279, 2000.
108. Ma Q, Li Y, Du J, Liu H, Kanazawa K, Nemoto T, Nakanishi H, Zhao Y. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides 27:841-849, 2006.
109. Reynolds D. Apolipoprotein E. In: Stanislaus Journal of Biochemical Reviews. Stanislaus: California State University, 1997.
110. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14:55-61, 1996.
111. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-483, 2002.
112. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, Trounce IA. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 25:672-679, 2005.
113. Squitti R, Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, Vernieri F, Rossi L, Baldassini M, Rossini PM. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64:1040-1046, 2005.
114. Squitti R, Rossini PM, Cassetta E, Moffa F, Pasqualetti P, Cortesi M, Colloca A, Rossi L, Finazzi-Agro A. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 32: 51-59, 2002.
115. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A, Baldvinsson M, Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease: a case-control study. Dement Geriatr Cogn Disord 9:239-242, 1998.
116. Sparks L. Cholesterol, copper, and accumulation of thioflavine S-reactive Alzheimer's-like amyloid beta in rabbit brain. J Mol Neurosci 24:97-104, 2004.
117. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676, 2001.
118. Phinney AL, Drisaldi B, Schmidt SD, Lugowski S, Coronado V, Liang Y, Horne P, Yang J, Sekoulidis J, Coomaraswamy J, Chishti MA, Cox DW, Mathews PM, Nixon RA, Carlson GA, St George-Hyslop P, Westaway D. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Assoc Am Physicians 100:14193-14198, 2003.
119. Bayer TA, Schafer S, Simons A, Kemmling A, Kamer T, Tepest R, Eckert A, Schussel K, Eikenberg O, Sturchler-Pierrat C, Abramowski D, Staufenbiel M, Multhaup G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Assoc Am Physicians 100:14187-14192, 2003.
120. Pajonk FG, Kessler H, Supprian T, Hamzei P, Bach D, Schweickhardt J, Herrmann W, Obeid R, Simons A, Falkai P, Multhaup G, Bayer TA. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alzheimers Dis 8:23-27, 2005.
121. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, Saafi L, Dissanayake AM, Cowan BR, Young AA, Occleshaw CJ, Chan YK, Leahy FE, Keogh GF, Gamble GD, Allen GR, Pope AJ, Boyd PD, Poppitt SD, Borg TK, Doughty RN, Baker JR. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53:2501-2508, 2004.
122. Eaton JW, Qian M. Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy. Mol Cell Biochem 234-235:135-142, 2002.
123. Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60: 379-385, 2003.
124. Brewer GJ. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets 5:195-202, 2005.
125. Brewer GJ, Ullenbruch MR, Dick RB, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141:210-216, 2003.
126. Askari FK, Dick RB, Mao M, Brewer GJ. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Biol Med 229:857-863, 2004.
127. Hou G, Dick R, Abrams GD, Brewer GJ. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146: 299-303, 2005.
128. Ma S, Hou G, Dick RD, Brewer GJ. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 4:419-426, 2004.
129. Brewer GJ, Dick R, Zeng C, Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 100:927-930, 2006.
130. Mandinov L, Mandinova A, Kyurkchiev S, Kyurkchiev D, Kehayov I, Kolev V, Soldi R, Bagala C, de Muinck ED, Lindner V, Post MJ, Simons M, Bellum S, Prudovsky I, Maciag T. Copper chelation represses the vascular response to injury. Proc Natl Acad Sci U S A 100:6700-6705, 2003.
131. Omoto A, Kawahito Y, Prudovsky I, Tubouchi Y, Kimura M, Ishino H, Wada M, Yoshida M, Kohno M, Yoshimura R, Yoshikawa T, Sano H. Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res Ther 7:R1174-1182, 2005.
132. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Thierry J, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6:1-10, 2000.
133. Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S. The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 139: 337-345, 2000.
134. Klevay LM. Cardiovascular disease from copper deficiency - a history. J Nutr 130:489S-492S, 2000.
135. Klevay LM. Hypercholesterolemia in rats produced by an increase in the ratio of zinc to copper ingested. Am J Clin Nutr 26:1060-1068, 1973.
136. Klevay LM, Pond WG, Medeiros DM. Decreased high density lipoprotein cholesterol and apoprotein A-I in plasma and ultrastructural pathology in cardiac muscle of young pigs fed a diet high in zinc. Nutr Res 14:1227-1239, 1994.